Regeneron Stock Falls 3.81% Following Positive Rival Trial Results

Key Facts

1Citigroup maintained a Neutral rating on Regeneron due to increasing competition in the ophthalmology sector.

2Kodiak Sciences announced positive Phase 3 trial results for eye drugs competing with Regeneron's Eylea.

3Regeneron's stock fell 3.81% to $757.99 following the competitive news.

Regeneron's stock fell 3.81% to $757.99 following news that Kodiak Sciences announced positive Phase 3 trial results for eye drugs. Financial Modeling Prep reported that these treatments compete directly with Regeneron's Eylea product, showing vision gains that are non-inferior to Eylea in treating wet age-related macular degeneration.

Citigroup maintained a Neutral rating on Regeneron due to increasing competition in the ophthalmology sector. REGN closed at $788.04 on September 25, 2026, while KOD closed at $32.35 on the same date. Within the financial sector, Citigroup (C) closed at $134.28 on September 25, 2026.